Abstract YO32
Case summary
Prostatic rhabdomyosarcoma in adult is a uncommon disease of adult. There are few cases reported as adult rhabdomyosarcoma of prostate. Most of the cases present with advanced stage. Modality of treatment vary from that of pediatric counterpart. Moreover stage wise treatment for adult disease are not well defined. We presented a young adult case of rhabdomyosarcoma presented with acute retention of urine and severe lower abdominal pain. After evaluation we thought of prostatic rhabdomyosarcoma which was later confirmed by IHC study. As the case was metastatic during presentation panel of experts recommend neoadjuvant chemotherapy followed by surgery according to the response of the treatment. There is no clear treatment plan recommendation for this advance stage, but we planned to evaluate Doxorubicin and Ifosphamide regimen for clinical trial. Surprisingly the systemic therapy works and after 3 cycle there was a very small residue persist. After almost complete response we recommended to continue further 3 cycle. Though surgery and radiation therapy Is the mainstay of treatment we can recommend neoadjuvant chemotherapy for metastatic rhabdomyosarcoma of prostate in adult from our clinical experience.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract